Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C

Bibliography

• Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147(927):258-67
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32
   PubMed Web of Science ®Google Scholar
• Thompson MR, Kaminski JJ, Kurt-Jones EA, Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011;3(6):920-40
   PubMed Web of Science ®Google Scholar
• Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8(7):559-68
   PubMed Web of Science ®Google Scholar
• David M. Interferons and microRNAs. J Interferon Cytokine Res 2010;30(11):825-8
   PubMed Web of Science ®Google Scholar
• Rajoriya N, Barnes E. Factors determining effectiveness of interferonsin managing hepatitis C: new targets and new approaches. Int J Interferon Cytokine Mediator Res 2010;2:85-95
   Google Scholar
• Ashfaq UA, Javed T, Rehman S, An overview of HCV molecular biology, replication and immune responses. Virol J 2011;8:161
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-9
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798-801
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005;202(4):461-5
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Herberman RB, Harvey C, A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci USA 1984;81(15):4926-9
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yano H, Sanou O, Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8. Hepatol Res 2002;24(2):99
   PubMed Web of Science ®Google Scholar
• Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006;25(3):349-60
   PubMed Web of Science ®Google Scholar
• Koyama T, Sakamoto N, Tanabe Y, Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006;34(1):41-9
   PubMed Web of Science ®Google Scholar
• Dubois A, Francois C, Descamps V, Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J 2009;6:70
   PubMedGoogle Scholar
• Scagnolari C, Trombetti S, Selvaggi C, In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol 2011;24(2):159-64
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Trombetti S, Solda A, Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interferon Cytokine Res 2011;31(6):475-9
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4(1):63-8
   PubMed Web of Science ®Google Scholar
• Ank N, West H, Bartholdy C, Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80(9):4501-9
   PubMed Web of Science ®Google Scholar
• Sommereyns C, Paul S, Staeheli P, IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4(3):e1000017
   PubMed Web of Science ®Google Scholar
• Diegelmann J, Beigel F, Zitzmann K, Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010;5(12):e15200
   PubMedGoogle Scholar
• Kanda T, Wu S, Kiyohara T, Interleukin-29 suppresses hepatitis a and C viral internal ribosomal entry site-mediated translation. Viral Immunol 2012;25(5):379-86
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. The IFN-γ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75(2):163-89
   PubMed Web of Science ®Google Scholar
• Witte K, Gruetz G, Volk HD, Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10(8):702-14
   PubMed Web of Science ®Google Scholar
• Jaitin DA, Roisman LC, Jaks E, Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006;26(5):1888-97
   PubMed Web of Science ®Google Scholar
• Jaks E, Gavutis M, Uze G, Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007;366(2):525-39
   PubMed Web of Science ®Google Scholar
• Antonelli G. Biological basis for a proper clinical application of alpha interferons. New Microbiol 2008;31(3):305-18
   PubMed Web of Science ®Google Scholar
• Thomas C, Moraga I, Levin D, Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011;146(4):621-32
   Google Scholar
• Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol 2010;10(2):123-30
   PubMed Web of Science ®Google Scholar
• Samarajiwa SA, Forster S, Auchettl K, INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 2009;37(Database issue):D852-7
   PubMedGoogle Scholar
• Espert L, Degols G, Gongora C, ISG20, a new interferon-induced RNase specific for single-stranded RNA, definesan alternative antiviral pathway against RNA genomic viruses. J Biol Chem 2003;278(18):16151-8
   PubMed Web of Science ®Google Scholar
• Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interferon Cytokine Res 2011;31(1):71-8
   PubMed Web of Science ®Google Scholar
• Kim KI, Zhang DE. ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun 307(3):431-4
   PubMed Web of Science ®Google Scholar
• Henriet S, Mercenne G, Bernacchi S, Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009;73(2):211-32
   PubMed Web of Science ®Google Scholar
• Lukic Z, Campbell EM. The cell biology of TRIM5alpha. Curr HIV/AIDS Rep 2012;9(1):73-80
   PubMedGoogle Scholar
• Kuhl BD, Cheng V, Wainberg MA, Liang C. Tetherin and its viral antagonists. J Neuroimmune Pharmacol 2011;6(2):188-201
   PubMed Web of Science ®Google Scholar
• Siegrist F, Ebeling M, Certa U. The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res 2011;31(1):183-97
   PubMed Web of Science ®Google Scholar
• Seo JY, Yaneva R, Cresswell P. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 2011;10(6):534-9
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Ikeda M, Matsumoto M, Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS ONE 2010;5(12):e14258
   PubMedGoogle Scholar
• Ding Q, Huang B, Lu J, Hepatitis C virus NS3/4A protease blocks IL-28 production. Eur J Immunol 2012;42(9):2374-82
   PubMed Web of Science ®Google Scholar
• Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 2005;32(2):86-91
   PubMed Web of Science ®Google Scholar
• Abe T, Kaname Y, Hamamoto I, Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007;81(17):8953-66
   PubMed Web of Science ®Google Scholar
• Kumthip K, Chusri P, Jilg N, Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 2012;86(16):8581-91
   PubMed Web of Science ®Google Scholar
• Kaukinen P, Sillanpaa M, Nousiainen L, Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J Med Virol 2013;85(1):71-82
   PubMed Web of Science ®Google Scholar
• Toroney R, Nallagatla SR, Boyer JA, Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A. J Mol Biol 2010;400(3):393-412
   PubMed Web of Science ®Google Scholar
• Han JQ, Barton DJ. Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 2002;8(4):512-25
   PubMed Web of Science ®Google Scholar
• Merup M, Tornebohm-Roche E, Engman K, Human leukocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alpha2a. Eur J Cancer 1994;30a:1729-30
   PubMed Web of Science ®Google Scholar
• Musch E, Malek M, von Eick H, Successful Long-term Application of Highly Purified Natural Interferon-alpha (Multiferon†) after Preceding Interferon Approaches in a ChronicHepatitis C Patient with Thrombocytopenia. Scand J Infect Dis 2004;00:1-4
   Google Scholar
• Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001;61(11):1661-91
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343(23):1666-72
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Moeller B, Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16(2):75-90
   PubMed Web of Science ®Google Scholar
• Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004;15:287-97
   PubMedGoogle Scholar
• Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
   PubMed Web of Science ®Google Scholar
• Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomizedcontrolled trials. Dig Dis Sci 2011;56(8):2221-6
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012;18(42):6060-9
   PubMed Web of Science ®Google Scholar
• Moreno-Otero R, Trapero-Marugan M, Gomez-Dominguez E, Is interferon-beta an alternative treatment for chronic hepatitis C? World J Gastroenterol 2006;12(17):2730-6
   PubMed Web of Science ®Google Scholar
• Osborn BL, Olsen HS, Nardelli B, Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-8
   PubMed Web of Science ®Google Scholar
• Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25:991-1002
   PubMed Web of Science ®Google Scholar
• De Leede LG, Humphries JE, Bechet AC, Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 2008;28:113-22
   PubMed Web of Science ®Google Scholar
• Muir AJ, Shiffman ML, Zaman A, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52(3):822-32
   PubMed Web of Science ®Google Scholar
• Konishi H, Okamoto K, Ohmori Y, An orally available, small-molecule interferon inhibits viral replication. Sci Rep 2012;2:259
   Google Scholar
• Lanford RE, Guerra B, Lee H, Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006;43(5):961-72
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034-9
   PubMed Web of Science ®Google Scholar
• Barouki FM, Witter FR, Griffin DE, Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987;7(1):29-39
   PubMedGoogle Scholar
• Witter F, Barouki F, Griffin D, Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. 1. Clin Pharmacol Ther 1987;42:567-75
   PubMed Web of Science ®Google Scholar
• von Wussow P, Pralle H, Hochkeppel HK, Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood 1991;78:38-43
   PubMed Web of Science ®Google Scholar
• Fuchs D, Norkrans G, Wejstal R, Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med 1992;1:196-200
   PubMedGoogle Scholar
• Imam H, Janson ET, Gobl A, Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. Anticancer Res 1995;15(5B):2191-5
   PubMed Web of Science ®Google Scholar
• Rodriguez JL, Valenzuela C, Marin N, Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers. Biotecnologia Aplicada 2000;17:166-70
   Google Scholar
• Motzer RJ, Rakhit A, Ginsberg M, Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001;19(5):1312-19
   PubMed Web of Science ®Google Scholar
• Silva M, Poo J, Wagner F, A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients withchronic hepatitis C (COMPARE). J Hepatol 2006;45(2):204-13
   PubMed Web of Science ®Google Scholar
• Bruno R, Sacchi P, Scagnolari C, Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controller study. Aliment Pharmacol Ther 2007;26(3):369-76
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Bellomi F, Trombetti S, Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 2007;147(2):270-6
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva CM, Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol 2010;10:15
   PubMedGoogle Scholar
• Scagnolari C, Zingariello P, Vecchiet J, Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J 2010;7:311
   PubMed Web of Science ®Google Scholar
• Giannelli G, Antonelli G, Fera G, 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993;13(1):57-60
   PubMedGoogle Scholar
• Antonelli G, Simeoni E, Turriziani O, Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999;19(3):243-51
   PubMed Web of Science ®Google Scholar
• Giannelli G, Guadagnino G, Dentico P, MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004;24(11):659-63
   PubMed Web of Science ®Google Scholar
• Chen L, Borozan I, Feld J, Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128(5):1437-44
   PubMed Web of Science ®Google Scholar
• Lau DT, Negash A, Chen J, Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2012;S0016-5085(12):01602-
   Google Scholar
• Abe H, Hayes CN, Ochi H, IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011;54(6):1094-101
   PubMed Web of Science ®Google Scholar
• Honda M, Sakai A, Yamashita T, Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139(2):499-509
   PubMed Web of Science ®Google Scholar
• Shi X, Pan Y, Wang M, IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. PLoS ONE 2012;7(5):e37054
   PubMed Web of Science ®Google Scholar
• Naggie S, Osinusi A, Katsounas A, Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012;56(2):444-54
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Birerdinc A, Estep M, The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med 2012;10:25
   PubMed Web of Science ®Google Scholar
• Li W, Jiang Y, Jin Q, Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. 2011;31(8):1118-26
   Google Scholar
• Dill MT, Duong FH, Vogt JE, Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31
   PubMed Web of Science ®Google Scholar
• Urban TJ, Thompson AJ, Bradrick SS, IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52(6):1888-96
   PubMed Web of Science ®Google Scholar
• Kong XF, Zhang XX, Gong QM, MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment. J Interferon Cytokine Res 2007;27(9):809-18
   PubMed Web of Science ®Google Scholar
• El Awady MK, Anany MA, Esmat G, Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 2011;26(5):843-50
   PubMed Web of Science ®Google Scholar
• Ren S, Yu H, Zhang H, Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection. Antiviral Res 2011;89(3):232-7
   PubMed Web of Science ®Google Scholar
• Stevenson NJ, Murphy AG, Bourke NM, Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 2011;6(11):e27866
   PubMedGoogle Scholar
• Antonelli G. In vivo development of antibody to interferons: an update to 1996. J Interferon Cytokine Res 1997;17:S39-46
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res 2012;32(3):95-102
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Casato M, Bellomi F, Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 2003;10(1):70-7
   PubMedGoogle Scholar
• Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 1999;10(3):413-22
   PubMed Web of Science ®Google Scholar
• van der Eijk AA, Vrolijk JM, Haagmans BL. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 2006;354(12):1323-4
   PubMed Web of Science ®Google Scholar
• Santantonio T, Milella M, Antonelli G, Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. J Hepatol 2006;45(5):759-61
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Trombetti S, Solda A, Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-alpha. Clin Microbiol Infect 2011
   Web of Science ®Google Scholar
• Nolte KU, Gunther G, von Wussow P. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Eur J Immunol 1996;26:2155-9
   PubMed Web of Science ®Google Scholar